This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

31.24 +0.60 (+1.96%)
Streaming Delayed Price Updated: 12:50 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
This once-beaten-down pharma stock remains an intriguing turnaround story. 
Via The Motley Fool
News headline image
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF... 
Via MarketMinute
Topics ETFs Intellectual Property Stocks
News headline image
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of... 
Via Finterra
Topics Economy Intellectual Property
News headline image
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗
Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide. 
Via The Motley Fool
News headline image
Teva Releases Q1 2026 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism
By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18,... 
Via Finterra
Topics Artificial Intelligence Economy Energy
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
The 3 Best Stocks to Invest $1,000 in Right Now ↗
These three high-quality stocks have ample growth potential. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗
Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding ↗
Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF). 
Via The Motley Fool
Topics Artificial Intelligence ETFs Retirement
News headline image
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
The Best Healthcare Stock to Invest $1,000 in Right Now ↗
There's nothing generic about this drugmaker's recent performance and continued prospects. 
Via The Motley Fool
News headline image
Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗
Sorry, Teva, it's not you ... it's me. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
Via Finterra
Topics Economy
News headline image
Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million ↗
This specialty retailer delivers personal care and home fragrance products through a broad network of stores and online channels. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Teva to Present at the Upcoming Investor Conferences in March
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Inside a $75 Million Albertsons Stock Sale as Shares Sink 8% in a Year ↗
Albertsons operates a nationwide grocery network, pairing in-house food production with a broad mix of retail and pharmacy services. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
AvePoint Stock Down 47% as One Fund Slashes Stake by $65.9 Million ↗
This technology firm offers cloud-based data management and compliance tools for organizations using Microsoft 365 and other platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment ↗
The application was based on data from a late-stage trial in which TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently... 
Via Stocktwits
News headline image
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗
The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome. 
Via Stocktwits
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.